Valuation : Sensorion

Market Cap 137M 159M 129M 117M 221M 15.06B 222M 1.52B 593M 7.66B 596M 583M 25.41B P/E 2026 *
-35.5x
P/E 2027 * -5.91x
Enterprise Value 4.92M 5.7M 4.62M 4.21M 7.92M 541M 7.96M 54.66M 21.28M 275M 21.39M 20.93M 912M EV / Sales 2026 *
0.22x
EV / Sales 2027 * 21.4x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.29%
1 week-1.29%
Current month-1.29%
1 month-3.78%
3 months-36.48%
6 months-26.60%
Current year-21.03%
1 week 0.23
Extreme 0.229
0.23
1 month 0.23
Extreme 0.229
0.25
Current year 0.19
Extreme 0.1902
0.65
1 year 0.19
Extreme 0.1902
0.65
3 years 0.12
Extreme 0.121
0.98
5 years 0.12
Extreme 0.121
2.24
10 years 0.12
Extreme 0.121
2.89
Manager TitleAgeSince
Chief Executive Officer 59 31/05/2026
Director of Finance/CFO - 25/06/2024
Chief Tech/Sci/R&D Officer - 10/12/2023
Director TitleAgeSince
Director/Board Member - 08/03/2015
Director/Board Member 43 -
Chairman 61 29/03/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.29%-1.29% - - 161M
+0.21%-2.69%+1.19%+17.32% 49.81B
+2.09%-0.71%+452.73%+498.77% 44.06B
-1.09%-0.41%+35.40%+15.17% 42.99B
-0.26%-4.71%+17.19%+71.67% 40.88B
-0.48%-3.09%+17.78%+49.80% 33.11B
-1.81%-5.02%+22.65%+113.24% 16.58B
-1.06%+2.87% - - 17.27B
-1.35%-3.40%+10.13%+26.34% 14.63B
-2.05%-5.14%+72.89%+34.69% 13.76B
Average -0.87%-1.91%+78.74%+103.38% 30.34B
Weighted average by Cap. -0.51%-2.00%+95.17%+120.43%

Financials

2026 *2027 *
Net sales 21.86M 25.34M 20.56M 18.73M 35.22M 2.4B 35.41M 243M 94.61M 1.22B 95.14M 93.08M 4.06B 6.4M 7.41M 6.02M 5.48M 10.31M 704M 10.36M 71.11M 27.68M 358M 27.83M 27.23M 1.19B
Net income -237K -274K -223K -203K -381K -26.04M -383K -2.63M -1.02M -13.25M -1.03M -1.01M -43.92M -36.12M -41.87M -33.98M -30.95M -58.21M -3.97B -58.52M -402M -156M -2.02B -157M -154M -6.7B
Net Debt -132M -153M -124M -113M -213M -14.52B -214M -1.47B -571M -7.39B -575M -562M -24.5B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change
01/09/26 €0.2290 -1.29%
31/08/26 €0.2320 -0.85%
28/08/26 €0.2340 0.00%
27/08/26 €0.2340 -1.68%
26/08/26 €0.2380 +2.59%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2660EUR
Average target price
1.138EUR
Spread / Average Target
+327.63%

Quarterly revenue - Rate of surprise